| Old | New | Differences | |
|---|---|---|---|
| 1 | - | ||
| 1 | + | Amended IN Senate May 16, 2024 Amended IN Senate March 18, 2024 CALIFORNIA LEGISLATURE 20232024 REGULAR SESSION Senate Bill No. 1442Introduced by Senators Ochoa Bogh and Skinner(Coauthor: Senator McGuire)February 16, 2024An act to add Section 127697.1 to the Health and Safety Code, relating to public health.LEGISLATIVE COUNSEL'S DIGESTSB 1442, as amended, Ochoa Bogh. Point-of-care tests for fentanyl.Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) to enter into partnerships, in consultation with other state departments as necessary, to, among other things, increase patient access to affordable drugs. Existing law authorizes CHHSA to enter into partnerships regarding over-the-counter naloxone products for the development, manufacturing, or distribution of those products, as specified. This bill would authorize CHHSA to enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration approved Administration-approved point-of-care tests for fentanyl to allow for the development, manufacturing, or distribution of those tests by any entity that is authorized to do so under federal or state law. Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO Bill TextThe people of the State of California do enact as follows:SECTION 1. Section 127697.1 is added to the Health and Safety Code, to read:127697.1. (a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law. (b) For purposes of this section, point-of-care test for fentanyl means a point-of-care test for use by providers a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine. | |
| 2 | 2 | ||
| 3 | - | ||
| 3 | + | Amended IN Senate May 16, 2024 Amended IN Senate March 18, 2024 CALIFORNIA LEGISLATURE 20232024 REGULAR SESSION Senate Bill No. 1442Introduced by Senators Ochoa Bogh and Skinner(Coauthor: Senator McGuire)February 16, 2024An act to add Section 127697.1 to the Health and Safety Code, relating to public health.LEGISLATIVE COUNSEL'S DIGESTSB 1442, as amended, Ochoa Bogh. Point-of-care tests for fentanyl.Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) to enter into partnerships, in consultation with other state departments as necessary, to, among other things, increase patient access to affordable drugs. Existing law authorizes CHHSA to enter into partnerships regarding over-the-counter naloxone products for the development, manufacturing, or distribution of those products, as specified. This bill would authorize CHHSA to enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration approved Administration-approved point-of-care tests for fentanyl to allow for the development, manufacturing, or distribution of those tests by any entity that is authorized to do so under federal or state law. Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO | |
| 4 | 4 | ||
| 5 | - | ||
| 5 | + | Amended IN Senate May 16, 2024 Amended IN Senate March 18, 2024 | |
| 6 | 6 | ||
| 7 | - | Amended IN Assembly June 13, 2024 | |
| 8 | 7 | Amended IN Senate May 16, 2024 | |
| 9 | 8 | Amended IN Senate March 18, 2024 | |
| 10 | 9 | ||
| 11 | 10 | CALIFORNIA LEGISLATURE 20232024 REGULAR SESSION | |
| 12 | 11 | ||
| 13 | 12 | Senate Bill | |
| 14 | 13 | ||
| 15 | 14 | No. 1442 | |
| 16 | 15 | ||
| 17 | - | Introduced by Senators Ochoa Bogh and Skinner(Coauthor: Senator McGuire) | |
| 16 | + | Introduced by Senators Ochoa Bogh and Skinner(Coauthor: Senator McGuire)February 16, 2024 | |
| 18 | 17 | ||
| 19 | - | Introduced by Senators Ochoa Bogh and Skinner(Coauthor: Senator McGuire) | |
| 18 | + | Introduced by Senators Ochoa Bogh and Skinner(Coauthor: Senator McGuire) | |
| 20 | 19 | February 16, 2024 | |
| 21 | 20 | ||
| 22 | 21 | An act to add Section 127697.1 to the Health and Safety Code, relating to public health. | |
| 23 | 22 | ||
| 24 | 23 | LEGISLATIVE COUNSEL'S DIGEST | |
| 25 | 24 | ||
| 26 | 25 | ## LEGISLATIVE COUNSEL'S DIGEST | |
| 27 | 26 | ||
| 28 | 27 | SB 1442, as amended, Ochoa Bogh. Point-of-care tests for fentanyl. | |
| 29 | 28 | ||
| 30 | - | Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) to enter into partnerships, in consultation with other state departments as necessary, to, among other things, increase patient access to affordable drugs. Existing law authorizes CHHSA to enter into partnerships regarding over-the-counter naloxone products for the development, manufacturing, or distribution of those products, as specified. This bill would authorize CHHSA to enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration-approved point-of-care tests for fentanyl to allow for the development, manufacturing, or distribution of those tests by any entity that is authorized to do so under federal or state law. | |
| 29 | + | Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) to enter into partnerships, in consultation with other state departments as necessary, to, among other things, increase patient access to affordable drugs. Existing law authorizes CHHSA to enter into partnerships regarding over-the-counter naloxone products for the development, manufacturing, or distribution of those products, as specified. This bill would authorize CHHSA to enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration approved Administration-approved point-of-care tests for fentanyl to allow for the development, manufacturing, or distribution of those tests by any entity that is authorized to do so under federal or state law. | |
| 31 | 30 | ||
| 32 | 31 | Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) to enter into partnerships, in consultation with other state departments as necessary, to, among other things, increase patient access to affordable drugs. Existing law authorizes CHHSA to enter into partnerships regarding over-the-counter naloxone products for the development, manufacturing, or distribution of those products, as specified. | |
| 33 | 32 | ||
| 34 | - | This bill would authorize CHHSA to enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration-approved point-of-care tests for fentanyl to allow for the development, manufacturing, or distribution of those tests by any entity that is authorized to do so under federal or state law. | |
| 33 | + | This bill would authorize CHHSA to enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration approved Administration-approved point-of-care tests for fentanyl to allow for the development, manufacturing, or distribution of those tests by any entity that is authorized to do so under federal or state law. | |
| 35 | 34 | ||
| 36 | 35 | ## Digest Key | |
| 37 | 36 | ||
| 38 | 37 | ## Bill Text | |
| 39 | 38 | ||
| 40 | - | The people of the State of California do enact as follows:SECTION 1. Section 127697.1 is added to the Health and Safety Code, to read:127697.1. (a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law. (b) For purposes of this section, point-of-care test for fentanyl means a point-of-care test for use by a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine. | |
| 39 | + | The people of the State of California do enact as follows:SECTION 1. Section 127697.1 is added to the Health and Safety Code, to read:127697.1. (a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law. (b) For purposes of this section, point-of-care test for fentanyl means a point-of-care test for use by providers a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine. | |
| 41 | 40 | ||
| 42 | 41 | The people of the State of California do enact as follows: | |
| 43 | 42 | ||
| 44 | 43 | ## The people of the State of California do enact as follows: | |
| 45 | 44 | ||
| 46 | - | SECTION 1. Section 127697.1 is added to the Health and Safety Code, to read:127697.1. (a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law. (b) For purposes of this section, point-of-care test for fentanyl means a point-of-care test for use by a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine. | |
| 45 | + | SECTION 1. Section 127697.1 is added to the Health and Safety Code, to read:127697.1. (a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law. (b) For purposes of this section, point-of-care test for fentanyl means a point-of-care test for use by providers a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine. | |
| 47 | 46 | ||
| 48 | 47 | SECTION 1. Section 127697.1 is added to the Health and Safety Code, to read: | |
| 49 | 48 | ||
| 50 | 49 | ### SECTION 1. | |
| 51 | 50 | ||
| 52 | - | 127697.1. (a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law. (b) For purposes of this section, point-of-care test for fentanyl means a point-of-care test for use by a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine. | |
| 51 | + | 127697.1. (a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law. (b) For purposes of this section, point-of-care test for fentanyl means a point-of-care test for use by providers a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine. | |
| 53 | 52 | ||
| 54 | - | 127697.1. (a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law. (b) For purposes of this section, point-of-care test for fentanyl means a point-of-care test for use by a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine. | |
| 53 | + | 127697.1. (a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law. (b) For purposes of this section, point-of-care test for fentanyl means a point-of-care test for use by providers a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine. | |
| 55 | 54 | ||
| 56 | - | 127697.1. (a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law. (b) For purposes of this section, point-of-care test for fentanyl means a point-of-care test for use by a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine. | |
| 55 | + | 127697.1. (a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law. (b) For purposes of this section, point-of-care test for fentanyl means a point-of-care test for use by providers a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine. | |
| 57 | 56 | ||
| 58 | 57 | ||
| 59 | 58 | ||
| 60 | 59 | 127697.1. (a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law. | |
| 61 | 60 | ||
| 62 | - | (b) For purposes of this section, point-of-care test for fentanyl means a point-of-care test for use by a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine. | |
| 61 | + | (b) For purposes of this section, point-of-care test for fentanyl means a point-of-care test for use by providers a provider to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine. |